|
Ausgabe
47
Spezifische
Immuntherapie: Vergleich SCIT und SLIT
Die Autoren der
Studie befragten von ihnen behandelte Allergiker nach ihrer
individuellen Meinung zu den beiden heute üblichen
Anwendungsformen der spezifischen Immuntherapie.
Patienten, die von der subkutanen Immuntherapie (SCIT) zur
sublingualen Anwendungsform wechselten beurteilten die (SLIT)
in 92% positiv.
Von den Patienten
die ausschließlich mit einer SLIT behandelt wurden gaben 90%
zu Protokoll, dass die sublinguale Form der spezifischen Immuntherapie
ihre Allergie-Symptome gelindert hat. (6)
Bitte beachten Sie unsere Datenschutzerklärung
hier
Eine englischsprachige Kurzversion
dieser Studie (sog. MEDLINE Abstract) finden Sie
hier
| Autor(en): |
Saporta D,
McDaniel AB |
| Titel: |
Efficacy comparison of multiple-antigen
subcutaneous injection immunotherapy and
multiple-antigen sublingual immunotherapy. |
| Journal: |
Ear Nose Throat J. 2007 Aug; 86(8): 493-7. |
| Bezug: |
ilanita@aol.com |
Abstract:
We performed an observational study to determine
whether allergen-specific sublingual immunotherapy (SLIT)
is as effective as allergen-specific subcutaneous
injection immunotherapy (SCIT).
Our study population was
comprised of 66 patients who had been taking SLIT. Of
this group, 36 patients had switched to SLIT after
having been treated with SCIT (group I), while the
remaining 30 patients had received SLIT only (group II).
A questionnaire was used to evaluate the results of
treatment. In group I, 33 patients (92%) gave SLIT a
favorable rating; 27 of these patients (75%) said it was
just as effective as SCIT and 6 (17%) said it was
actually superior(the remaining 3 patients [8%] said
that SCIT was better).
In group II, 27 of 30 patients
(90%) said they had attained symptom relief with SLIT;
21 (70%) said that the relief had been very significant.
Overall, 60 of the 66 patients (91%) expressed various
degrees of satisfaction with SLIT
We believe that our
SLIT protocol, which is based on established guidelines
for SCIT administration, is an effective, safe,
well-tolerated, and easy-to-use regimen. Future
prospective studies of larger groups are clearly
indicated.
| PubMed-ID: |
17915673 |
| ISSN: |
0145-5613 (Print) |
| Erstellungsdatum: |
05.10.2007 |
|
